共查询到20条相似文献,搜索用时 101 毫秒
1.
《中国肿瘤临床与康复》2015,(2)
目的探讨老年局部晚期非小细胞肺癌(NSCLC)患者同期放化疗和序贯放化疗的临床疗效和不良反应。方法回顾性分析100例局部晚期NSCLC患者资料,采用随机表抽签法分为同期放化疗组和序贯放化疗组,每组50例,比较两组患者的近期疗效、不良反应和生活质量。结果序贯放化疗组患者的总有效率为58.0%,显著低于同期放化疗组(80.0%,P<0.05);同期放化疗组患者的Ⅲ~Ⅳ级血小板减少及急性放射性食管炎发生率分别64.0%和48.0%,明显高于序贯放化疗组(42.0%和26.0%,P<0.05)。治疗前,两组患者躯体功能及总健康状况评分差异无统计学意义(P>0.05);治疗1个月后,同步放化疗组躯体功能及总健康状况评分显著高于序贯放化疗组(P<0.05)。结论相比于序贯放化疗,同期放化疗可提高局部晚期NSCLC的临床疗效及生活质量,不良反应虽比序贯放化疗大,但经积极治疗未出现治疗相关死亡病例,适合在临床上推广。 相似文献
2.
徐海平 《中华肿瘤防治杂志》2012,19(9):704-706
为了观察局部进展期胃癌术后同步放化疗的疗效及不良反应,对74例局部进展期胃癌术后患者,随机分为对照组和观察组各37例,对照组单纯采用奥沙利铂、亚叶酸钙联合5-氟尿嘧啶辅助化疗;观察组采用同步放化疗,放射治疗采用6MVX线,放射总剂量30~40 Gy/(3~5周).结果观察组的1、2和3年生存率分别为75.7%、64.9%和54.1%,对照组为67.6%、43.2%和27.0%,差异有统计学意义,x2=16.81,P=0.02.观察组的3年无瘤生存率(59.6%)显著高于对照组(21.6%),x2=11.62,P=0.03.不良反应主要为骨髓抑制和胃肠道反应,观察组胃肠道反应的发生率显著高于对照组,x2 =7.94,P=0.01.初步研究结果提示,术后同步放化疗可以提高局部进展期胃癌患者的生存率,且不良反应可耐受,值得在临床借鉴. 相似文献
3.
目的:了解CEF序贯NP方案新辅助化疗在局部晚期乳腺癌治疗中的疗效和毒副反应.方法:38例ⅡB期~ⅢB期的局部晚期乳腺癌患者术前接受新辅助化疗,CEF方案环磷酰胺(CTX)500mg/m2,d1,静脉注射;表柔比星(EPI)60mg/m2,d1,静脉注射;5-氟尿嘧啶(5-FU)500mg/m2,d1,持续4h静脉滴入,21d为1个周期,共3个周期后接受NP方案:诺维苯(NVB)25mg/m2,静脉推注,d1、d8;顺铂(DDP)30mg/m2,静脉滴入,d1~d3,并适量水化,每21d为1个周期,共3个周期.分别观察新辅助化疗后肿瘤原发病灶和区域淋巴结的缓解情况,以及毒副反应.结果:原发病灶临床有效率为92.1%(35/38),其中CR63.2%(24/38),PR28.9%(11/38),SD7.9%(3/18);pCR为31.6%(12/38).22例化疗前细针穿刺活检明确区域淋巴结转移阳性的患者中,8例(36.4%)术后病理腋淋巴结转移阴性.毒副反应主要为白细胞减少症、脱发和恶心/呕吐,共有30例(78.9%)患者发生了Ⅲ~Ⅳ度的白细胞减少症.结论:CEF序贯NP新辅助化疗方案在局部晚期乳腺癌的治疗中疗效显著,耐受性良好. 相似文献
4.
放化疗同步及序贯治疗中晚期食管癌 总被引:8,自引:1,他引:7
冀法欣 《中国肿瘤临床与康复》1999,6(3):84-85
目的观察放化疗同步及序贯治疗中晚期食管癌的疗效。资料与方法1992年6月至1997年6月,采用随机分组对140例食管癌进行放化同步及序贯治疗,并与118例单纯放射治疗结果进行对比。结果放化疗同步组、放化疗序贯组有效率为91%和83.3%,单纯放射治疗组75.7%(P<0.05);前两组1、2年生存率为82%、52%和80%、47%,后组为51%、27%(P<0.05)。中位生存期放化疗同步组与序贯组为17.5与14.5个月,单纯放疗组为8.6个月。前两组局部复发率、远处转移率均明显低于后组。结论放化疗同步、序贯治疗中晚期食管癌与单纯放射治疗组相比可明显提高有效率,1、2年生存率及中位生存期,并可降低局部复发率及远处转移率,但对3、4年生存率未见明显优势。 相似文献
5.
目的 分析晚期三阴性乳腺癌(TNBC)的临床特征,探讨影响其预后的因素.方法 收集1999年1月至2007年12月间134例晚期TNBC患者的临床资料,回顾性研究其临床特点、生存状况及预后因素.结果 134例患者确诊为晚期TNBC的中位年龄为45岁.6例为初治Ⅳ期,128例为初治Ⅰ一Ⅲ期,经手术等治疗后出现局部复发或远处转移.14例为局部复发及区域淋巴结转移,75例为远处转移,45例患者为同时出现局部复发及远处转移.最常见的远处转移部位是肺,其中51.7%(62/120)的患者同时出现2个部位以上的转移.随访至2009年6月30日,死亡75例(56.0%).全组患者的中位总生存时间(OS)为26.5个月(95%C/为20.5~32.6个月),1、3、5年预期总生存率分别为80.9%、37.1%和30.1%.初诊转移部位为单发骨转移患者预后好,7例患者的中位OS为84.2个月.111例晚期接受一线方案化疗的患者中位OS为28.5个月,23例未接受化疗的患者中位OS为12.6个月,差异有统计学意义(P=0.0001).一线化疗有效(完全缓解+部分缓解)患者45例,疾病稳定患者39例,疾病进展患者12例.化疗有效患者的中位OS为36.1个月,明显高于疾病稳定患者(20.8个月)和进展患者(14.0个月),差异有统计学意义(P=0.0108).单因素预后分析结果显示,是否远处转移、复发转移后是否接受化疗以及一线化疗疗效对患者的5年OS有显著影响(P<0.05).Cox比例风险模型分析结果显示,是否接受一线化疗以及一线化疗疗效是影响晚期TNBC预后的独立因素.结论,TNBC易早期出现局部复发和远处转移,且内脏转移及多部位转移的比率较高,可能与其侵袭性高和缺乏有效的治疗手段有关.晚期TNBC患者预后较差,化疗能够改善其预后.Abstract: Objective To characterize the sites of distant recurrence and clinical outcomes in a cohort of Chinese patients with metastatic triple-negative breast cancer (TNBC ). Methods One hundred and thirty-four patients with metastatic TNBC treated at Cancer Hospital of CAMS from January 1999 to December 2007 were included in this study. Hie clinicopathological features and long-term survival of the patients were retrospectively analyzed. Results The median age of the patients was 45 years. Most patients (72.7% ) had a higher predilection for visceral metastasis and early recurrence within the first two years of follow-up. Six patients (4.5%) presented with stage Ⅳ disease, 14 patients were diagnosed with locoregional recurrence after mastectomy, 75 patients with distant metastases, and 45 patients with both locoregional recurrence and distant metastasis. The most common site of first recurrence was the lung, and 62(51.7% )of the patients had more than two sites of metastasis. By July 30, 2009, 75 patients died of breast cancer (56.0%). The median overall survival (OS) was 26. 5 months [95% confidence interval (CI), 20. 5-32. 6 months]. The l-,3- and 5-year overall survivals ( OS) were 80. 9% ,37. 1% and 30.1% , respectively. The median overall survival time of 58 patients with single site of metastasis was 28.5 months, longer than that of patients with more than two sites of metastases. Patients whose initial distant recurrence was bone metastasis only (7 patients) had better prognosis, with a median OS of 84.2 months. The median OS (28.5 vs. 12.6 months, P =0.0001) differed significantly between patients who received first-line chemotherapy and those who did not. Forty-five of the 96 patients with measurable disease achieved complete/partial response (CR/PR), 39 patients had stable disease (SD), and 12 patients had disease progression (PD). The median OS was 36.1 months in patients with CR/PR, 20. 8 months with SD, and 14 months with PD, respectively. The median OS of patients with CR/PR was significantly longer than that of patients with SD/PD (P =0. 0106). Distant metastasis, first-line chemotherapy and clinical response were significantly related with OS by univariate analysis. Furthermore, first-line chemotherapy and the clinical response were demonstrated to be an independent prognostic factor by multivariate analysis. Conclusions Recurrence risk and mortality are considerably higher in TNBC patients within the early years of follow-up. TNBC patients have a higher risk of multiple and visceral metastases, and poorer survival, which might attribute to its aggressive clinical behavior and lack of effective regimens. Our findings also suggest that chemotherapy can effectively improve the clinical outcome of those patients. 相似文献
6.
局部晚期胃癌术后同步放化疗临床研究 总被引:3,自引:0,他引:3
目的观察局部晚期胃癌术后辅助同步放化疗的临床疗效。方法将79例胃癌患者随机分为A组和B组。A组39例,第1次ECF化疗结束3周后开始同步放化疗。放疗采用常规四野照射6、0Co和6/15MV直线加速器、三维适型放疗,35天为1周期。放疗第1天及放疗结束前3天均分别行CF+5-FU方案化疗1周,后继续ECF方案化疗3周期。B组40例,术后单纯ECF方案化疗6周期。结果 A组1、2、5年复发率分别为12.8%、17.9%、23.1%,B组1、2、5年复发率分别为20.0%、32.5%、45.0%,两组比较差异有统计学意义(P〈0.05);A组1、2、5年生存率分别为89.7%、71.8%、48.7%,B组为80.0%、50.0%、30.0%,差异有统计学意义(P〈0.05)。结论同步放化疗是局部晚期胃癌相对理想的辅助治疗手段。 相似文献
7.
子宫颈癌根治术后同步放化疗与放疗序贯化疗及单纯放疗临床对比研究 总被引:2,自引:2,他引:0
目的:探讨子宫颈癌根治术后高危患者同步放化疗与放疗+化疗序贯治疗、单纯放疗的疗效及毒副反应.方法:117例宫颈癌术后高危患者分为同步放化疗组、放疗+化疗序贯治疗组和单纯放疗组3组,各39例.3组放疗方案相同.第1组在放疗第1周内同时给予FP方案化疗;第2组在放疗结束后1周给予FP方案化疗.结果:3组3年盆腔复发率分别为2.6%、17.9%和23.1%.第1组与第2、3组比较差异有统计学意义,x2=6.532,P=0.011,3组3年远处转移率分别为2.6%、12.8%和25.6%,第1、2组与第3组比较差异有统计学意叉,x2=6.936,P=0.008;3组3年生存率分别为94.7%、74.4%和61.5%,第1组与第2、3组比较差异有统计学意义,x2=10.268,P=0.001.第1组骨髓抑制和消化道反应发生率均高于第2、3组,x2值分别为14.204和13.882,P值均为0.000,但大部分患者能够耐受.结论:子宫颈癌术后高危患者同步放化疗组与放疗+化疗序贯治疗、单放组比较,降低了3年盆腔复发率,减少了3年远处转移率,提高了3年生存率,且早期毒副反应能耐受. 相似文献
8.
Objective To characterize the sites of distant recurrence and clinical outcomes in a cohort of Chinese patients with metastatic triple-negative breast cancer (TNBC ). Methods One hundred and thirty-four patients with metastatic TNBC treated at Cancer Hospital of CAMS from January 1999 to December 2007 were included in this study. Hie clinicopathological features and long-term survival of the patients were retrospectively analyzed. Results The median age of the patients was 45 years. Most patients (72.7% ) had a higher predilection for visceral metastasis and early recurrence within the first two years of follow-up. Six patients (4.5%) presented with stage Ⅳ disease, 14 patients were diagnosed with locoregional recurrence after mastectomy, 75 patients with distant metastases, and 45 patients with both locoregional recurrence and distant metastasis. The most common site of first recurrence was the lung, and 62(51.7% )of the patients had more than two sites of metastasis. By July 30, 2009, 75 patients died of breast cancer (56.0%). The median overall survival (OS) was 26. 5 months [95% confidence interval (CI), 20. 5-32. 6 months]. The l-,3- and 5-year overall survivals ( OS) were 80. 9% ,37. 1% and 30.1% , respectively. The median overall survival time of 58 patients with single site of metastasis was 28.5 months, longer than that of patients with more than two sites of metastases. Patients whose initial distant recurrence was bone metastasis only (7 patients) had better prognosis, with a median OS of 84.2 months. The median OS (28.5 vs. 12.6 months, P =0.0001) differed significantly between patients who received first-line chemotherapy and those who did not. Forty-five of the 96 patients with measurable disease achieved complete/partial response (CR/PR), 39 patients had stable disease (SD), and 12 patients had disease progression (PD). The median OS was 36.1 months in patients with CR/PR, 20. 8 months with SD, and 14 months with PD, respectively. The median OS of patients with CR/PR was significantly longer than that of patients with SD/PD (P =0. 0106). Distant metastasis, first-line chemotherapy and clinical response were significantly related with OS by univariate analysis. Furthermore, first-line chemotherapy and the clinical response were demonstrated to be an independent prognostic factor by multivariate analysis. Conclusions Recurrence risk and mortality are considerably higher in TNBC patients within the early years of follow-up. TNBC patients have a higher risk of multiple and visceral metastases, and poorer survival, which might attribute to its aggressive clinical behavior and lack of effective regimens. Our findings also suggest that chemotherapy can effectively improve the clinical outcome of those patients. 相似文献
9.
Objective To characterize the sites of distant recurrence and clinical outcomes in a cohort of Chinese patients with metastatic triple-negative breast cancer (TNBC ). Methods One hundred and thirty-four patients with metastatic TNBC treated at Cancer Hospital of CAMS from January 1999 to December 2007 were included in this study. Hie clinicopathological features and long-term survival of the patients were retrospectively analyzed. Results The median age of the patients was 45 years. Most patients (72.7% ) had a higher predilection for visceral metastasis and early recurrence within the first two years of follow-up. Six patients (4.5%) presented with stage Ⅳ disease, 14 patients were diagnosed with locoregional recurrence after mastectomy, 75 patients with distant metastases, and 45 patients with both locoregional recurrence and distant metastasis. The most common site of first recurrence was the lung, and 62(51.7% )of the patients had more than two sites of metastasis. By July 30, 2009, 75 patients died of breast cancer (56.0%). The median overall survival (OS) was 26. 5 months [95% confidence interval (CI), 20. 5-32. 6 months]. The l-,3- and 5-year overall survivals ( OS) were 80. 9% ,37. 1% and 30.1% , respectively. The median overall survival time of 58 patients with single site of metastasis was 28.5 months, longer than that of patients with more than two sites of metastases. Patients whose initial distant recurrence was bone metastasis only (7 patients) had better prognosis, with a median OS of 84.2 months. The median OS (28.5 vs. 12.6 months, P =0.0001) differed significantly between patients who received first-line chemotherapy and those who did not. Forty-five of the 96 patients with measurable disease achieved complete/partial response (CR/PR), 39 patients had stable disease (SD), and 12 patients had disease progression (PD). The median OS was 36.1 months in patients with CR/PR, 20. 8 months with SD, and 14 months with PD, respectively. The median OS of patients with CR/PR was significantly longer than that of patients with SD/PD (P =0. 0106). Distant metastasis, first-line chemotherapy and clinical response were significantly related with OS by univariate analysis. Furthermore, first-line chemotherapy and the clinical response were demonstrated to be an independent prognostic factor by multivariate analysis. Conclusions Recurrence risk and mortality are considerably higher in TNBC patients within the early years of follow-up. TNBC patients have a higher risk of multiple and visceral metastases, and poorer survival, which might attribute to its aggressive clinical behavior and lack of effective regimens. Our findings also suggest that chemotherapy can effectively improve the clinical outcome of those patients. 相似文献
10.
局部晚期胃癌术后同步放化疗研究进展 总被引:1,自引:0,他引:1
胃癌是全球最常见的恶性肿瘤之一,尽管其发病率在近几十年问呈下降趋势,但在世界每年新发肿瘤中胃癌仍占10%,并占所有死亡病例的12%。尤其在日本、中国、西欧和拉丁美洲等地区,胃癌已成为主要的癌症死因。因胃癌患者临床症状不典型,就诊时多为局部晚期,根治性手术(R0切除)是其唯一的治愈手段, 相似文献
11.
目的:对比观察局部晚期乳腺癌改良根治术后多西他赛同步放化疗与序贯放疗的放射性不良反应,评估多西他赛同步放化疗模式的安全性、可行性。方法:收集2009年1 月至2014年12月广西医科大学第四附属医院155 例女性乳腺癌病例,患者均行乳腺癌改良根治术,病理诊断为乳腺浸润性导管癌,TNM 分期为pT3~4pN1~3cM0 或p 任意TpN 2~3cM0。采用氟尿嘧啶+ 表柔比星+ 环磷酰胺(FEC )化疗方案后,密闭信封法随机分为同步组(多西他赛化疗时同步放疗)78例、序贯组(多西他赛化疗完成后放疗)77例,观察两组放射性不良反应及近期疗效。结果:中位随访39(16~62)个月。同步组和序贯组的放射性不良反应轻微,均无3~4 级放射性皮肤反应、症状性心肺放射损伤。1~2 级放射性皮肤反应同步组的发生率为89.7%(70/ 78)、序贯组为88.3%(68/ 77),两组比较差异无统计学意义(P > 0.05)。 3 年无复发生存率同步组为92.3%(72/ 78),序贯组为81.8%(63/ 77),两组比较差异具有统计学意义(P = 0.046)。 结论:局部晚期乳腺癌改良根治术后多西他赛同步放化疗的放射性不良反应轻微,与序贯治疗比较提高了患者的3 年无复发生存率,安全可行,可作为局部晚期乳腺癌的治疗选择。 相似文献
12.
王莉 《中华肿瘤防治杂志》2007,14(14):1102-1103
为评价以国产多西紫杉醇(商品名多帕菲)联合顺铂治疗晚期乳腺癌的近期疗效和不良反应。多帕菲60mg/m^2,静脉滴入,d1;顺铂80mg/m^2,静脉滴入,d1~d3。21d为1个周期,一般至少用2个周期后评价疗效。全组35例,CR4例,PR16例,SD7例,PD8例,总有效率(CR+PR)57.1%。初治有效率62.5%,复治有效率55、5%。主要不良反应为骨髓抑制,其次为胃肠道反应。以多帕菲联合顺铂的化疗方案对晚期乳腺癌呈现较高疗效,同时多帕菲具有使用方便、安全,优异的性价比,不失为一种好的解救化疗方案。 相似文献
13.
长春瑞滨联合顺铂治疗晚期乳腺癌疗效观察 总被引:3,自引:0,他引:3
对有病理学诊断及可评价客观指标的30例患者给予NP方案治疗,即采用长春瑞滨(NVB)25mg/m^2,静脉滴入,d1、d8;顺铂(DDP)30mg/m^2,静脉滴入,d1~d3,21d为1个周期,平均约3~6个周期。30例患者中有效率为53.3%(16/30),CR4例,PR12例,SD10例,PD4例。主要毒性为骨髓抑制,其发生率为93.3%。初步临床观察结果提示,NVB+DDP治疗晚期乳腺癌疗效较好,毒性反应可以耐受。 相似文献
14.
局部进展期直肠癌术前放化疗的疗效评价 总被引:6,自引:1,他引:5
目的 分析临床病理变化特征,对局部进展期直肠癌手术前放化疗的进行评价。方法 36例局部进展期直肠癌患者行手术前放化疗。放疗总剂量为45Gy,每周5次,每次1.8Gy。全身化疗共2个疗程,四氢叶酸(folinic acid,FA)50mg,静脉滴入,随后静脉给予5-Fu 300mg/m^2。手术后2-4周开始追加2-4个疗程化疗。辅助治疗完成后4-6周采取手术治疗。结果 仅有2例(5.6%)患者出现Ⅲ度造血系统毒性反应,全组未出现Ⅲ-Ⅳ度胃肠反应、皮肤或泌尿系急性毒性反应。全部患者均采取手术治疗,全组无围手术期死亡,手术并发症为13.8%,未发生远期并发症。经过术前辅助治疗,肿瘤的平均直径平均缩小28.0%。4例(11.1%)达到病理完全缓解,病理总有效率(CR+PR)为77.8%,肿瘤分期下降率达到52.8%。辅助治疗后,淋巴结的阴转率达到60.0%,淋巴结总阳性率由83.0%降至37.0%。结论 术前放疗+全身化疗安全可靠,能使部分肿瘤病理完全缓解,缩小原发瘤,减少了局部淋巴结转移率,从而达到降低肿瘤分期,提高了手术的疗效。 相似文献
15.
局部晚期乳腺癌的保留乳房手术 总被引:2,自引:1,他引:1
乳腺癌是女性最常见的恶性肿瘤之一,局部晚期乳腺癌(LABC)的治疗是世界范围内的临床难题,影响着乳腺癌总体生存率的提高。LABC的涵盖范围伴随着TNM分期系统的修订而不断变化。已有的研究证明,新辅助化疗后可以进行保留乳房手术(BCT),但要严格掌握适应证,保留乳房手术的指征已逐渐取得共识。开始治疗之前准确记录或定位肿瘤,要保证足够的阴性切缘。对于腋窝淋巴结手术问题仍有争议,多数主张常规进行清除手术。预后上不差于早期乳腺癌作保留乳房手术后的局部复发率。 相似文献
16.
序贯化疗在乳腺癌辅助治疗中的研究进展 总被引:1,自引:0,他引:1
随着新的活性药物的出现和细胞生长动力学模型概念应用于临床,乳腺癌辅助化疗的疗效得到了一定的提高.序贯化疗的治疗方式在一定程度上改善了辅助治疗的疗效和治疗指数.本文对近年来序贯化疗在乳腺癌辅助治疗中临床研究进展进行了回顾. 相似文献
17.
目的 探讨单药顺铂与TP(紫杉醇+顺铂)方案同步放化疗治疗中晚期子宫颈癌的临床疗效及不良反应比较.方法 随机入组44例局部中晚期子宫颈癌患者随机给予单药顺铂方案或TP方案化疗,两组同期放疗均采用盆腔外照射+高剂量率腔内后装.结果 所有患者均完成治疗,治疗结束3月评价其有效率,TP组为66.7 %,顺铂组为55.0%.1年生存率分别为88.3%、70.0%,差异无统计学意义(P值>0.05).毒副反应主要是粒细胞减少、胃肠道反应.同期放化疗期间TP组、单药顺铂组发生Ⅲ~Ⅳ度粒细胞减少和Ⅲ~Ⅳ度胃肠道反应分别为16.7%vs5.0%(P>O.05),12.5% vs 5.0%(P>0.05).结论 TP方案与单药顺铂同期放化疗治疗局部中晚期子宫颈癌患者的疗效比较,前者的近期疗效及1年生存率均较后者有所提高,差异无统计学意义(P>0.05),但从百分率来看,TP组在近期疗效及1年生存率方面均有升高的趋势.尽管联合化疗方案中出现Ⅲ、Ⅳ度放化疗反应的病例数较单药组有所增加,但可以耐受,不影响治疗的完成. 相似文献
18.
长春瑞滨联合顺铂治疗晚期乳腺癌疗效观察 总被引:1,自引:0,他引:1
对有病理学诊断及可评价客观指标的30例患者给予NP方案治疗,即采用长春瑞滨(NVB)25mg/m2,静 脉滴入,d1、d8;顺铂(DDP)30mg/m2,静脉滴入,d1~d3,21d为1个周期,平均约3~6个周期。30例患者中有效率 为53.3%(16/30),CR4例,PR12例,SD10例,PD4例。主要毒性为骨髓抑制,其发生率为93.3%。初步临床观察 结果提示,NVB+DDP治疗晚期乳腺癌疗效较好,毒性反应可以耐受。 相似文献
19.
长春瑞滨联合顺铂治疗多柔比星耐药的晚期转移性乳腺癌疗效观察 总被引:2,自引:0,他引:2
观察长春瑞滨(NVB)联合顺铂(DDP)治疗多柔比星(ADM)耐药的晚期转移性乳腺癌的疗效及毒性.32例既往使用ADM治疗后复发转移的晚期乳腺癌患者,其中单纯癌5例,浸润性导管癌25例,大汗腺样癌1例,硬癌1例.采用NVB 25 mg/m^2,静脉滴入,d1、d8;DDP 25 mg/m^2,静脉滴入,d1~d3.21 d为1个周期,每2~3个周期评定疗效.完全缓解(CR)1例,部分缓解(PR)17例,稳定(SD)7例,进展(PD)7例,总有效率为56.3%(18/32).主要毒性为骨髓抑制,Ⅲ~Ⅳ度白细胞下降发生率为53.1%(17/32).其他为恶心、呕吐、贫血、静脉炎等.初步研究结果提示,NvB联合DDP治疗ADM耐药的晚期转移性乳腺癌疗效确切,毒性反应可耐受,值得临床应用. 相似文献
20.
紫杉醇联合顺铂治疗57例晚期乳腺癌的临床疗效分析 总被引:1,自引:0,他引:1
目的:观察紫杉醇联合顺铂(DDP)方案治疗晚期乳腺癌(ABC)及蒽环类耐药性乳腺癌的疗效与安全性.方法:采用紫杉醇联合DDP方案治疗ABC 57例(其中含蒽环类耐药性乳腺癌26例).紫杉醇175 mg/m^2,静脉滴入,d1(或分为d1、d8);DDP 70 mg/m^2,静脉滴入,d1(或分为d1~d3),加水化、利尿和止吐治疗,21 d为1个周期.本组中位化疗周期数为3个.结果:完全缓解6例,部分缓解24例,稳定16例,疾病进展11例,总的有效率52.6%(30/57),26例蒽环类耐药性乳腺癌患者的有效率为61.5%(16/26).治疗时一般情况较好者疗效(53.5%)好于一般情况差者(23.3%),P=0.045.中位肿瘤进展时间7个月,1年生存率为61.4%,中位生存期为19个月.主要毒性反应为骨髓抑制及胃肠道反应.结论:紫杉醇和DDP联合方案治疗ABC,特别是蒽环类耐药性乳腺癌疗效较好,使用方便,毒性反应较轻.该方案是包括蒽环类耐药性ABC的有效解救治疗方案. 相似文献